What happens if I stop using Baricitinib? Does all the progress disappear?

Baricitinib, a medication originally developed to treat rheumatoid arthritis, was approved in 2022 in the US for adults with severe alopecia areata, an autoimmune disease that causes sudden hair loss. Many people who have seen positive results with this treatment ask a very important question: What happens if I stop using it? Will all the progress be lost?

This question is entirely valid, especially considering the emotional and financial investment required to follow a long-term pharmaceutical treatment. In this article, we address that concern using available scientific evidence.

How long-lasting is the progress with Baricitinib compared to other treatments?

In BRAVE-AA1, 38.8% of adults on 4 mg reached 80% or more scalp coverage by week 36 (vs 6.2% on placebo); results build over months, not weeks.

It’s important to note that, like minoxidil, progress with Baricitinib is not immediate and does not guarantee full hair regrowth in all cases.

Response varies depending on the severity of alopecia areata, the duration of the condition, and individual immune system factors. Because regrowth builds over months, doctors usually give it time before judging the response. Stopping early may limit regrowth, as Baricitinib works by modulating an inflammatory pathway (JAK-STAT) responsible for the autoimmune attack on hair follicles. As long as this pathway remains active and untreated, the autoimmune process is likely to continue.

Relapse: A common scenario after stopping Baricitinib

The one randomised withdrawal study so far (BRAVE-AA1, described below) found a high rate of relapse after baricitinib was stopped. This means many people experience renewed hair loss once the treatment stops.

In the BRAVE-AA1 trial, 40 people who had regained 80% or more scalp coverage after a year were switched to placebo: none had lost that benefit by 4 weeks, about 1 in 10 had by 8 weeks, and 80% had by week 152, compared with 7% of those who continued. 26 of the 32 who restarted baricitinib regained it (King et al., JAMA Dermatology 2024). In other words, for most people the progress was not sustained without ongoing treatment. Baricitinib works by blocking a cell-signaling pathway known as JAK-STAT, which is involved in the autoimmune inflammation that attacks hair follicles. When the medication is stopped, this signaling is reactivated, and the immune system resumes its attack on the follicles, leading to renewed hair loss.

Is it possible to maintain results without Baricitinib?

So far, there is no strong evidence showing that the results achieved with Baricitinib can be maintained permanently after discontinuation. In the BRAVE-AA1 withdrawal study described above, 80% of responders switched to placebo had lost their benefit by week 152. For those who stayed on treatment, about 9 in 10 week-52 responders still had 80% or more coverage at week 104 (Senna et al., 2024). Some researchers have suggested that after achieving significant improvement, it may be possible to attempt a gradual dose reduction to test whether the body can maintain results without the drug. However, this approach is not yet supported by long-term studies with large sample sizes.

What are the risks of abruptly stopping an immunomodulator like Baricitinib?

Baricitinib is not known to cause a “withdrawal syndrome” like some psychiatric medications or corticosteroids, but it is important to understand that it is a powerful immunomodulator. In the withdrawal trial, loss of regrowth after stopping was gradual — none by 4 weeks, about 1 in 10 by 8 weeks. However, in people who also have inflammatory conditions such as rheumatoid arthritis, stopping the medication can worsen joint symptoms or lead to systemic flare-ups. This is why specialists emphasize that any dosage change should be done under medical supervision. Baricitinib is not an over-the-counter drug. It must be prescribed by a healthcare professional and requires a prescription in most countries due to its potential side effects and its impact on the immune system.

Discontinuing Baricitinib without a follow-up strategy often results in losing the regrown hair. Stopping is not known to cause harm in itself, but relapse is, according to current evidence, highly likely.

This is because the medication does not “cure” alopecia areata; it controls the disease as long as it is being used.

Moreover, since it is an immunomodulator originally approved for another condition (rheumatoid arthritis), its prescription and supervision should be handled by a physician experienced in alopecia—preferably a dermatologist. This includes selecting the correct dose and planning for any potential discontinuation. Staying on baricitinib long term means ongoing exposure to the risks in its FDA boxed warning — serious infections, death from any cause, cancer, major cardiovascular events and blood clots — which is why the decision to continue or stop is made with a dermatologist. The label also says to avoid live vaccines and warns the drug may harm an unborn baby.

For this reason, if you're considering stopping the treatment, it's best to speak with your dermatologist to explore future options, assess your specific clinical case, and discuss possible maintenance therapies. Science is still investigating how to sustain benefits long-term without indefinite reliance on immunomodulatory drugs.

User Experiences

Community feedback on stopping Baricitinib consistently reflects a shared concern about the loss of progress after discontinuation. In one of the most detailed and directly relevant threads, users discussed the temporary nature of results with Baricitinib, particularly in the context of treating alopecia areata, an autoimmune condition. One individual expressed frustration after learning that hair regrowth from JAK inhibitors like Baricitinib is often lost once treatment ends. Other users confirmed this, stating that relapse is common unless the drug is continued, with regrown hair often shedding within weeks to months after cessation.

Several users noted that while Baricitinib is effective for initiating hair regrowth in many patients, it acts more as a disease suppressor than a cure. As one user put it, "the moment you stop, the immune system goes back to attacking the follicles." Another commenter, identifying themselves as a dermatologist, reiterated that long-term use may be necessary and warned of the high recurrence rate when patients stop taking the medication. There were also reports of users switching to other JAK inhibitors or combining therapies (like corticosteroids) to attempt to sustain regrowth, but the sentiment remained cautious. Users mentioned the cost and potential side effects—like changes in lipid levels and risk of infections—as key reasons why continuous treatment is difficult or undesirable. In summary, the community consensus is that stopping Baricitinib leads to a high likelihood of losing all or most of the hair regrowth it induced. It's viewed as a maintenance therapy rather than a permanent fix, requiring ongoing administration to preserve results.

references

King, B., Ohyama, M., Kwon, O., et al. (2022). Two phase 3 trials of baricitinib for alopecia areata. New England Journal of Medicine, 386(18), 1687–1699. https://doi.org/10.1056/NEJMoa2110343

U.S. National Library of Medicine. OLUMIANT (baricitinib) tablets, prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=866e9f35-9035-4581-a4b1-75a621ab55cf

King B, Ko J, Kwon O, et al. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial. JAMA Dermatol. 2024;160(10):1075-1081. https://pubmed.ncbi.nlm.nih.gov/39141364/

Senna M, Mostaghimi A, Ohyama M, et al. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. J Eur Acad Dermatol Venereol. 2024;38(3):583-593. https://pubmed.ncbi.nlm.nih.gov/38391212/

Reddit user. (2023, June 28). Anyone heard of or have experience using baricitinib? r/tressless. https://reddit.com/r/tressless/comments/14kv4wk/anyone_heard_of_or_have_experience_using/baricitinib

Reddit user. (2023, February 9). What are the odds baricitinib will get a topical otc version for androgenic alopecia? r/tressless. https://reddit.com/r/tressless/comments/10y9lxi/what_are_the_odds_baricitinib_will_get_a_topical/

Reddit user. (2022, September 3). I am a dermatologist with a clinical interest in alopecia. AMA. r/tressless. https://reddit.com/r/tressless/comments/x4jltq/i_am_a_dermatologist_with_a_clinical_interest_in/

Reddit user. (2024, October 5). What else is good. Besides the big 3. r/tressless. https://reddit.com/r/tressless/comments/1fwfoxu/what_else_is_good_besides_the_big_3/

For more community discussions and research, search "Baricitinib" at https://tressless.com/search/Baricitinib.